From: Cytokine-induced killer cells promote antitumor immunity
Year | Tumor type | No. of cases | Culture condition | Authors |
---|---|---|---|---|
1999 | Renal cell carcinoma Colorectal carcinoma Lymphoma | 10 | IFN-γ, anti-CD3, IL2 plus IL-2 transgene | Schmidt-Wolf IG et al. [33] |
2005 | Lymphoma | 9 | IFN-γ, anti-CD3, and IL2 | Leemhuis T et al. [14] |
2006 | Gastric carcinoma | 57 | IFN-γ, anti-CD3, IL2 and IL-1alpha | Jiang JT et al. [34] |
2007 | Leukemia | 11 | IFN-γ, anti-CD3 and IL2 | Introna M et al. [35] |
2008 | Non-small cell lung cancer | 59 | IFN-γ, anti-CD3, IL2 and IL-1alpha | Wu CP et al. [36] |
2009 | Hepatocellular carcinoma | 127 | IFN-γ, anti-CD3, IL2 and IL-1lalpha | Hui D et al. [37] |
2009 | Renal cell carcinoma and lymphoma | 6 | IFN-γ, anti-CD3, and IL2 | Olioso P et al. [38] |
2010 | Gastric carcinoma | 156 | IFN-γ, anti-CD3, IL2, and IL-1alpha | Jiang JT et al. [39] |
2011 | relapsed hematologic malignancies | 18 | IFN-γ, anti-CD3, and IL2 | Laport GG et al. [40] |
2012 | Renal cell carcinoma | 74 | IFN-γ, anti-CD3, IL2, IL-1beta | Liu L et al. [41] |